PR Newswire | Jan 14, 2022 07:07AM EST

Closing Bell on Friday January 14, 2022

01/14 06:06 CST

Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to Ring the Nasdaq Stock Market Closing Bell on Friday January 14, 2022 EASTWOOD, Australia, Jan. 14, 2022

EASTWOOD, Australia, Jan. 14, 2022 /PRNewswire/ -- Bionomics Limited (Nasdaq: BNOX, ASX: BNO), a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, will ring the Nasdaq Closing Bell remotely from around the globe.

Dr Errol De Souza, Executive Chairman, will ring the Closing Bell alongside the Company's team in a virtual bell ringing ceremony.

When:FRIDAY, JANUARY 14, 2021 - 3:45 p.m. to 4:00 p.m. ET

WebcastA live stream of the Nasdaq Closing Bell will be available at: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/nasdaq.

For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq

Photos:To obtain a hi-resolution photograph of the Market Close, please go to https://www.nasdaq.com/marketsite/bell-ringing-ceremony and click on the market close of your choice.

FOR FURTHER INFORMATION PLEASE CONTACT:

General: Investor Relations:

Ms Suzanne Irwin Mr. Connor Bernstein

Company Secretary Vice President, Strategy and Corporate Development

+61 8 8150 7400 +1 (831) 246 3642

CoSec@bionomics.com.au cbernstein@bionomics.com.au

About Bionomics Limited:Bionomics (Nasdaq: BNOX, ASX:BNO) is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the 7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Bionomics1, or at www.bionomics.com.au.

About Nasdaq:Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

View original content: https://www.prnewswire.com/news-releases/bionomics-limited-nasdaq-bnox-asx-bno-to-ring-the-nasdaq-stock-market-closing-bell-on-friday-january-14-2022-301461190.html

SOURCE Bionomics Limited